For the year ending 2025-12-31, KRYS has $1,333,794K in assets. $114,234K in debts. $496,304K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 496,304 | |||
| Short-term investments | 331,487 | |||
| Accounts receivable, net | 127,425 | |||
| Inventory | 40,475 | |||
| Prepaid taxes | 14,006 | |||
| Prepaid expenses and other current assets | 14,905 | |||
| Total current assets | 1,024,602 | |||
| Property and equipment, net | 150,776 | |||
| Long-term investments | 128,066 | |||
| Right-of-use assets | 7,239 | |||
| Deferred tax asset, net of valuation allowance | 22,824 | |||
| Other non-current assets | 287 | |||
| Total assets | 1,333,794 | |||
| Accounts payable | 3,238 | |||
| Current portion of lease liability | 1,771 | |||
| Accrued rebates | 58,181 | |||
| Accrued expenses and other current liabilities | 39,752 | |||
| Total current liabilities | 102,942 | |||
| Lease liability | 7,568 | |||
| Other long-term liabilities | 3,724 | |||
| Total liabilities | 114,234 | |||
| Additional paid-in capital | 1,194,261 | |||
| Accumulated other comprehensive income (loss) | 1,136 | |||
| Retained earnings (accumulated deficit) | 24,163 | |||
| Total stockholders equity | 1,219,560 | |||
| Total liabilities and stockholders equity | 1,333,794 | |||
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)